Cellectis S.A. CLLS
1.07 USD +0.01 (+1.02%)
As ofNov 18, 2026, 1:33 PM EST
1.03 Day range 1.09
0.881 52-week range 5.45
- YTD
- -77.88%
- 1 year
- -73.95%
News
seekingalpha.com Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
marketbeat.com What Cellectis (CLLS) Said on Its Q3 Earnings Call Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…benzinga.com Update: Cellectis Q3 Adj. EPS $(0.59) Misses $(0.17) Estimate, Sales $5.439M Miss $15.615M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.17) by 247.06 percent. This is a 3050 percent decrease over earnings of $0.02…
globenewswire.com Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026); lancement de…
globenewswire.com Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of…benzinga.com Cellectis Q3 EPS $(0.61) Misses $(0.17) Estimate, Sales $5.439M Miss $15.615M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.17) by 258.82 percent. This is a 6200 percent decrease over earnings of $0.01…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Lisata Therapeutics (NASDAQ:LSTA) stock rose 37.2% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. BioStem Technologies…
